Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Dec 2021
Price :
$35
*
At a glance
- Drugs Mirikizumab (Primary) ; Secukinumab
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms OASIS-2
- Sponsors Eli Lilly and Company; Eli Lilly Japan
- 30 Mar 2021 Results published in the ClinicalTrials.gov Trial Registry
- 19 Mar 2021 Results published in the European Clinical Trials Database Trial Registry
- 20 Aug 2020 Status changed from active, no longer recruiting to completed.